Drug Trial Radar · NCT00542425
Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis
Last checked: Nov 20, 2026Latest source record: Oct 30, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Apr 2007
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- Radius Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 11, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 55 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether BA058 is effective in building bone in postmenopausal women with osteoporosis.
Conditions
- Osteoporosis
Interventions
teriparatideDrug
teriparatide 20 µg subcutaneous daily
PlaceboDrug
Placebo subcutaneous daily
BA058 20 µgDrug
BA058 20 µg subcutaneous daily
BA058 40 µgDrug
BA058 40 µg subcutaneous daily
BA058 80 µgDrug
BA058 80 µg subcutaneous daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Marker of Bone Metabolism, PINPTime frame: 6 months
- Change in Bone Mineral Density, Total Spine.Time frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Radius Health, Inc.
Cambridge, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.